topicBerberine Lipid Profile Meta-Analysis
claimThis review was based on a narrative literature search designed to identify experimental, clinical, and translational evidence linking natural products with gut barrier integrity, gut microbiota, low-grade inflammation, and metabolic endotoxemia.
evidence level3
citationŠantić Roko (2026)
sourceNatural Bioactive Compounds Targeting Gut Barrier Integrity and Metabolic Endotoxemia in Cardiometabolic Disease: Mechanistic Insights and Translational Perspectives
topicBerberine Lipid Profile Meta-Analysis
claimBecause this article is a narrative review rather than a systematic review, formal risk-of-bias assessment and quantitative evidence synthesis were not performed.
evidence level3
citationŠantić Roko (2026)
sourceNatural Bioactive Compounds Targeting Gut Barrier Integrity and Metabolic Endotoxemia in Cardiometabolic Disease: Mechanistic Insights and Translational Perspectives
topicBerberine Lipid Profile Meta-Analysis
claimOver the past two decades, accumulating evidence has repositioned the gastrointestinal tract from a passive absorptive organ to an immunologically active barrier whose functional state directly influences systemic inflammatory tone and metabolic homeostasis [].
evidence level3
citationŠantić Roko (2026)
sourceNatural Bioactive Compounds Targeting Gut Barrier Integrity and Metabolic Endotoxemia in Cardiometabolic Disease: Mechanistic Insights and Translational Perspectives
topicBerberine Lipid Profile Meta-Analysis
claimReference lists of relevant reviews and primary studies were additionally screened to identify articles not captured by database searches.
evidence level3
citationŠantić Roko (2026)
sourceNatural Bioactive Compounds Targeting Gut Barrier Integrity and Metabolic Endotoxemia in Cardiometabolic Disease: Mechanistic Insights and Translational Perspectives
topicBerberine Lipid Profile Meta-Analysis
claimFive strategies were analyzed for individuals with ASSIGN risk scores ≥20% and ≥10%: no intervention, atorvastatin 20 mg/day, berberine 1000 mg/day, simvastatin 20 mg plus berberine 1500 mg/day, and simvastatin 20 mg plus berberine 900 mg/day.
evidence level4
citationXia Y (2026)
sourceCost-effectiveness of statins, berberine, and combination for primary cardiovascular disease prevention in Scotland.
topicBerberine Lipid Profile Meta-Analysis
claimWe aim to estimate and compare the cost-effectiveness of statins, berberine, and their combined use for primary cardiovascular disease (CVD) prevention.
evidence level4
citationXia Y (2026)
sourceCost-effectiveness of statins, berberine, and combination for primary cardiovascular disease prevention in Scotland.
topicBerberine Lipid Profile Meta-Analysis
claimThe Scottish CVD Policy Model was used to predict long-term health and cost outcomes in Scottish adults aged 40 years or older without pre-existing CVD.
evidence level4
citationXia Y (2026)
sourceCost-effectiveness of statins, berberine, and combination for primary cardiovascular disease prevention in Scotland.